Celcuity Inc. (CELC) Covered Calls
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted oncology therapies. The company utilizes its proprietary CELsignia platform to analyze live patient tumor cells, identifying specific pathway activities to guide treatment. Its lead therapeutic candidate, gedatolisib, is an investigational inhibitor targeting the PI3K, AKT, and mTOR signaling pathways. Celcuity primarily develops treatments for advanced breast cancer and other solid tumor indications.
You can sell covered calls on Celcuity Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CELC (prices last updated Fri 4:16 PM ET):
| Celcuity Inc. (CELC) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 115.00 | -0.24 | 114.00 | 129.50 | 797K | - | 5.3 |
| Covered Calls For Celcuity Inc. (CELC) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 115 | 6.00 | 123.50 | -6.9% | -167.9% | |
| Apr 17 | 115 | 11.40 | 118.10 | -2.6% | -22.1% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Celcuity Inc. is a clinical-stage biotechnology company that is seeking to change the paradigm of cancer treatment through a functional cellular analysis approach. While traditional genomics focus on mutations, Celcuity’s proprietary CELsignia platform analyzes the underlying signaling pathway activity within a patient’s live tumor cells. This technology is designed to identify the specific drivers of a patient’s cancer, allowing for more precise selection of targeted therapies that may improve clinical outcomes.
The company’s lead therapeutic program is gedatolisib, a potent small molecule that inhibits all four isoforms of PI3K as well as the mTOR complex. This dual-mechanism approach is intended to overcome the resistance many patients develop to standard endocrine therapies. Celcuity is currently conducting late-stage clinical trials to evaluate the efficacy of this candidate in combination with other approved drugs for patients with metastatic breast cancer and other solid tumors.
Competition
The oncology market is highly competitive, with several large pharmaceutical companies developing inhibitors for the same cellular pathways. Direct competitors in the PI3K/mTOR and breast cancer space include Novartis, Pfizer, and Eli Lilly. Additionally, the company faces competition from other biotech firms like AstraZeneca and Gilead Sciences, which are also advancing targeted therapies and antibody-drug conjugates.
Strategic Outlook and Innovation
Strategic innovation at Celcuity is focused on the continued expansion of the CELsignia platform to support a broader range of solid tumors. By validating new signaling pathway tests, the company aims to identify additional patient populations that could benefit from its lead drug candidate or other targeted inhibitors. This patient-centric diagnostic approach is a key differentiator in the crowded oncology field, as it provides a functional rather than purely genetic map of the disease.
The company is also prioritizing the advancement of its clinical pipeline through strategic collaborations and rigorous trial designs. The focus remains on securing regulatory approvals for its lead candidate in underserved breast cancer segments. By integrating its unique diagnostic technology with its therapeutic development, Celcuity intends to build a sustainable pipeline of treatments that address the high rate of therapy resistance in advanced cancer patients.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | MRVL covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | REPL covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | QURE covered calls | |
| 5. | IBIT covered calls | 10. | SOFI covered calls | 5. | PATH covered calls | |
Want more examples? CEG Covered Calls | CELH Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
